Showing results (1091-1100 of 1,526) with videos related to
Sort By:
Pageof 153
CPT: Pharmacometrics & Systems Pharmacology|April 18, 2024
Population pharmacokinetics of intraperitoneal irinotecan and SN-38 in patients with peritoneal metastases from colorectal originPascale C S Rietveld, Sebastiaan D T Sassen, Niels A D Guchelaar, et al.CPT: Pharmacometrics & Systems Pharmacology|May 8, 2024
Navigating the landscape of parameter identifiability methods: A workflow recommendation for model developmentMartijn van Noort, Martijn Ruppert, Joost DeJongh, et al.CPT: Pharmacometrics & Systems Pharmacology|April 5, 2024
Physiologically based pharmacokinetics modeling and transporter proteomics to predict systemic and local liver and muscle disposition of statinsLuna Prieto Garcia, Anna Vildhede, Pär Nordell, et al.CPT: Pharmacometrics & Systems Pharmacology|April 10, 2024
Construction of a prognostic model based on memory CD4+ T cell-associated genes for lung adenocarcinoma and its applications in immunotherapyYong Li, Xiangli Ye, Huiqin Huang, et al.CPT: Pharmacometrics & Systems Pharmacology|October 19, 2023
Cluster Gauss-Newton method for a quick approximation of profile likelihood: With application to physiologically-based pharmacokinetic modelsYasunori Aoki, Yuichi SugiyamaCPT: Pharmacometrics & Systems Pharmacology|October 26, 2023
Multistate modeling for survival analysis in critically ill patients treated with meropenemYaru Peng, Iris K Minichmayr, Han Liu, et al.CPT: Pharmacometrics & Systems Pharmacology|September 11, 2023
Combining pharmacometric models with predictive and prognostic biomarkers for precision therapy in Crohn's disease: A case study of brazikumabNan Zhang, Ming Liang Chan, Jing Li, et al.CPT: Pharmacometrics & Systems Pharmacology|September 5, 2023
Evaluation of postprandial total triglycerides within the TIGG model for characterizing postprandial response of glucose, insulin, and GLP-1Jennifer Leohr, Maria C KjellssonCPT: Pharmacometrics & Systems Pharmacology|September 5, 2023
How large must a dose-optimization trial be?David C NorrisCPT: Pharmacometrics & Systems Pharmacology|September 14, 2023
Model based assessment of food and acid reducing agent effects on oral absorption of mezigdomide (CC-92480), a novel cereblon E3 ligase modulatorFan Wu, Liangang Liu, Allison Gaudy, et al.Pageof 153